ライフサイエンスコーパス: fibrillation

1 boembolic events-European Registry in Atrial Fibrillation).

2 or subclinical and clinical new-onset atrial fibrillation).

3 s with both paroxysmal and persistent atrial fibrillation.

4 than 2% of admissions were always in atrial fibrillation.

5 vely inhibits both Abeta oligomerization and fibrillation.

6 ndex were among the top predictors of atrial fibrillation.

7 et if there was no prior diagnosis of atrial fibrillation.

8 d specific stroke mechanisms, such as atrial fibrillation.

9 s and NOACs (n=71 681) in nonvalvular atrial fibrillation.

10 hromboembolic events in patients with atrial fibrillation.

11 one of the most potent antagonists of Abeta fibrillation.

12 that pH serves as an on/off switch for betaS fibrillation.

13 associated with an increased risk of atrial fibrillation.

14 duced ventricular tachycardia or ventricular fibrillation.

15 hromboembolism even in the absence of atrial fibrillation.

16 ronic treatments to all patients with atrial fibrillation.

17 rdiac atrial disorders independent of atrial fibrillation.

18 on around the world for patients with atrial fibrillation.

19 s into the trigger and maintenance of atrial fibrillation.

20 ke/systemic embolism in patients with atrial fibrillation.

21 or harmful in patients with ESRD and atrial fibrillation.

22 ulation is underused in patients with atrial fibrillation.

23 nagement of patients with nonvalvular atrial fibrillation.

24 tal findings on inhibiting full-length Abeta fibrillation.

25 ial infarction, non-fatal stroke, and atrial fibrillation.

26 g cardiac dysrhythmias, most commonly atrial fibrillation.

27 t disease, heart failure, stroke, and atrial fibrillation.

28 one of the most potent antagonists of Abeta fibrillation.

29 bleeding in patients with nonvalvular atrial fibrillation.

30 uch as the long-QT syndrome (LQT) and atrial fibrillation.

31 cardiomyopathy given its parallels to atrial fibrillation.

32 arfarin for patients with nonvalvular atrial fibrillation.

33 r disease, stroke, heart failure, and atrial fibrillation.

34 tachycardias converted to VT or ventricular fibrillation.

35 ions, stroke severity, and history of atrial fibrillation.

36 history of ischemic heart disease or atrial fibrillation.

37 her rates of device complications and atrial fibrillation.

38 rence of ventricular tachycardia/ventricular fibrillation.

39 indicated after the first episode of atrial fibrillation.

40 dial infarction, non-fatal stroke, or atrial fibrillation.

41 8.9% had ventricular tachycardia/ventricular fibrillation.

42 een associated with increased risk of atrial fibrillation.

43 thromboembolism, QT prolongation, and atrial fibrillation.

44 chycardia (IART) (61.6%), followed by atrial fibrillation (28.8%), and focal atrial tachycardia (9.5%

45 evalence of hypotension (57% vs 48%), atrial fibrillation (50% vs 40%), and other adverse events did

46 ) with heart failure, 109 (9.2%) with atrial fibrillation, 89 (8%) with myocardial infarction, 11 (0.

47 METHODS AND Patients undergoing first atrial fibrillation ablation and postinterventional esophageal

48 been reported with all modalities of atrial fibrillation ablation despite esophageal temperature mon

49 there nevertheless data that support atrial fibrillation ablation in asymptomatic patients?

50 Thus, the only indication for atrial fibrillation ablation in recent guidelines has been the

51 AEF complicating atrial fibrillation ablation is associated with a high mortalit

52 We prospectively studied 33 AT (post- atrial fibrillation ablation or surgical mitral valve repair).

53 total, 1802 patients underwent first atrial fibrillation ablation procedure between January 2013 and

54 ation that occurs in 0.1% to 0.25% of atrial fibrillation ablation procedures.

55 foration is a dreaded complication of atrial fibrillation ablation that occurs in 0.1% to 0.25% of at

56 Since the original description of atrial fibrillation ablation, numerous studies have demonstrate

57 t pain that start days or weeks after atrial fibrillation ablation.

58 ardiac symptoms within 2 months of an atrial fibrillation ablation.

59 of intracardiac electrograms to guide atrial fibrillation (AF) ablation has yielded conflicting resul

60 LA) fibrosis is a strong predictor of atrial fibrillation (AF) ablation success and has been associat

61 sure (BP) lowering prevents recurrent atrial fibrillation (AF) after catheter ablation in patients wi

62 K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular heart disease

63 Atrial fibrillation (AF) and heart failure with reduced ejectio

64 Atrial fibrillation (AF) and left ventricular systolic dysfunct

65 Atrial fibrillation (AF) and stroke are important major health

66 Both obesity and atrial fibrillation (AF) are increasing in epidemic proportions

67 (CHD) are assumed to be vulnerable to atrial fibrillation (AF) as a result of residual shunts, anomal

68 n to prevent stroke for patients with atrial fibrillation (AF) but are often underused in community p

69 schemic stroke rates in patients with atrial fibrillation (AF) but increase the risk of bleeding.

70 ry artery evaluation in patients with atrial fibrillation (AF) by using invasive coronary angiography

71 ly published analysis of contemporary atrial fibrillation (AF) cohorts showed an association between

72 e long-term probability of developing atrial fibrillation (AF) considering genetic predisposition and

73 challenging in patients with extended atrial fibrillation (AF) duration and persistent/long-standing

74 ge of Cardiology/Heart Rhythm Society atrial fibrillation (AF) guidelines.

75 Atrial fibrillation (AF) has a substantial genetic basis.

76 Atrial fibrillation (AF) has been reported as a strong independ

77 The prevalence of atrial fibrillation (AF) has risen significantly over the past

78 Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels of NT-p

79 se-dependent termination of simulated atrial fibrillation (AF) in the absence of AF-induced electrica

80 Atrial fibrillation (AF) is a common arrhythmia that poses a si

81 Atrial fibrillation (AF) is a common arrhythmia.

82 Atrial fibrillation (AF) is a common cardiac disease in aging p

83 Atrial fibrillation (AF) is an all-too-common and often challen

84 Subclinical atrial fibrillation (AF) is associated with an increased risk f

85 Atrial fibrillation (AF) is common in heart failure (HF), but t

86 Prevalence of atrial fibrillation (AF) is increasing, due partly to the agein

87 Asymptomatic atrial fibrillation (AF) is increasingly common in the aging po

88 Atrial fibrillation (AF) is the most common cardiac arrhythmia

89 Atrial fibrillation (AF) is the most common cardiac arrhythmia,

90 Whether the pattern of atrial fibrillation (AF) modifies the risk/benefit of anticoagu

91 Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist.

92 s role on prognosis in anticoagulated atrial fibrillation (AF) patients and determined whether its ad

93 to the quality of anticoagulation in atrial fibrillation (AF) patients, reflected by time in therape

94 the leading cause of mortality among atrial fibrillation (AF) patients.

95 y has been associated with drivers of atrial fibrillation (AF) risk, including left ventricular and p

96 teract with risk factors to influence atrial fibrillation (AF) risk.

97 h manifestation of MetS is related to atrial fibrillation (AF) risks.

98 reasing focus on the rising burden of atrial fibrillation (AF) since the turn of the millennium.

99 cardiomyopathy patients for new-onset atrial fibrillation (AF) was explored.

100 is associated with atrial remodeling, atrial fibrillation (AF), and increased incidence of arrhythmia

101 Atrial tachy-arrhytmias, such as atrial fibrillation (AF), are characterised by irregular electr

102 for thromboembolism in patients with atrial fibrillation (AF), but less is known about how diabetes

103 iants at >30 loci that associate with atrial fibrillation (AF), including rare coding mutations in th

104 l treatment, and clinical outcomes of atrial fibrillation (AF), sustained ventricular arrhythmias, an

105 Atrial fibrillation (AF), the most common sustained arrhythmia

106 ipose tissue (EAT) is associated with atrial fibrillation (AF), the most frequent cardiac arrhythmia.

107 ted conflicting mechanisms underlying atrial fibrillation (AF), with the spatial resolution of data o

108 ating evidence links inflammation and atrial fibrillation (AF).

109 stitute a new target for treatment of atrial fibrillation (AF).

110 e (TV) may occur secondary to chronic atrial fibrillation (AF).

111 roke prevention in most patients with atrial fibrillation (AF).

112 ornerstone of ablation for persistent atrial fibrillation (AF).

113 advances in the clinical treatment of atrial fibrillation (AF).

114 equently antecede onset of paroxysmal atrial fibrillation (AF).

115 ound on brain MRI among patients with atrial fibrillation (AF).

116 on fraction in either sinus rhythm or atrial fibrillation (AF).

117 e left atrium, potentially leading to atrial fibrillation (AF).

118 rs to the self-perpetuating nature of atrial fibrillation (AF).

119 ovascular disease (ASCVD) events, and atrial fibrillation (AFib) in a multiethnic cohort.

120 (PVR) still determines recurrences of atrial fibrillation after contact force (CF)-guided pulmonary v

121 n predicts incident heart failure and atrial fibrillation; among patients with heart failure, it stro

122 WAS) included 17,931 individuals with atrial fibrillation and 115,142 referents; the exome-wide assoc

123 Danish cohort study of patients with atrial fibrillation and a single stroke risk factor, there was

124 Patients were included who had atrial fibrillation and an indication for oral anticoagulation.

125 to the risk of stroke associated with atrial fibrillation and as a determinant of arrhythmia progress

126 tolic function and is associated with atrial fibrillation and cardiovascular outcomes.

127 As to treat patients with nonvalvular atrial fibrillation and concomitant aspirin therapy.

128 angerous heart diseases, such as ventricular fibrillation and congestive heart failure.

129 h preexcitation had higher hazards of atrial fibrillation and heart failure.

130 ts and patients and then according to atrial fibrillation and mitral regurgitation status.

131 There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhag

132 eventing recurrences of nonparoxysmal atrial fibrillation and reducing hospital admissions.

133 resent in the EGM recordings only for atrial fibrillation and some atrial flutter propagations patter

134 eentrant arrhythmias, leading to ventricular fibrillation and sudden cardiac death.

135 lation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction [CAMERA-MRI]; ACTR

136 important role in the development of atrial fibrillation and that CLICs and structural type IV colla

137 efits were seen in both patients with atrial fibrillation and venous thromboembolism.

138 ted cardiac arrest or documented ventricular fibrillation and ventricular tachycardia (lasting >/=30

139 identified determinants of new-onset atrial fibrillation and, using propensity matching, characteriz

140 arization, incident heart failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocardial in

141 its its functions including oligomerization, fibrillation, and cytotoxicity.

142 ndent risk factor for both stroke and atrial fibrillation, and in the setting of AF, type 2 diabetes

143 use of medications for heart failure, atrial fibrillation, and left ventricular systolic dysfunction.

144 athy, cardiac conduction disturbance, atrial fibrillation, and malignant ventricular arrhythmias.

145 insights into the molecular basis of atrial fibrillation, and may facilitate the identification of n

146 ause of age but also stroke severity, atrial fibrillation, and prestroke functional limitations.

147 higher rates of acute kidney injury, atrial fibrillation, and transfusion requirements, whereas TAVR

148 organisation of care, knowledge about atrial fibrillation, and treatment options.

149 rdial breakthrough waves (EBW) during atrial fibrillation are important elements of the arrhythmogeni

150 rt disease, atrial septal defect, and atrial fibrillation are made, and the arrhythmia (atrial fibril

151 fibrosis in patients with persistent atrial fibrillation are mandatory and may inform strategies to

152 ke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial reported that apixaban th

153 were obtained from 17 simulations of atrial fibrillation, atrial flutter, and focal atrial tachycard

154 oubles the likelihood of freedom from atrial fibrillation, atrial flutter, or atrial tachycardia whil

155 locus led to ventricular arrhythmias, atrial fibrillation, atrioventricular conduction defects, and d

156 therapy in patients with nonvalvular atrial fibrillation because these drugs have several benefits o

157 short-term mortality, renal failure, atrial fibrillation, bleeding, and length of intensive care uni

158 ent clinics if they had no history of atrial fibrillation but had any of the following: CHA2DS2-VASc

159 of stroke than warfarin in trials of atrial fibrillation, but large-scale evaluations in clinical pr

160 ght is an independent risk factor for atrial fibrillation, but the underlying mechanisms are unknown.

161 ons of this simulation, patients with atrial fibrillation can be triaged to an optimal warfarin thera

162 tion study (GWAS) that included 8,180 atrial fibrillation cases and 28,612 controls with follow-up in

163 prevention, suffered more often from atrial fibrillation, chronic kidney disease, diabetes mellitus,

164 ides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin, with additional red

165 patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiodarone, fluconazole,

166 bocytopenia, acute coronary syndrome, atrial fibrillation, congestive heart failure, DM 2, and smokin

167 thways undertaken by various proteins during fibrillation could be discerned.

168 ogy consultation, anticoagulation for atrial fibrillation, discharge on statin, lipid management, neu

169 atients with long-standing persistent atrial fibrillation (duration, 12-72 months) underwent phase/fr

170 tients with diabetes also had a lower Atrial Fibrillation Effects on Quality of Life score of 80 (int

171 Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391).

172 petitive ventricular tachycardia/ventricular fibrillation episodes alternating with periods of sinus

173 d those with an antecedent history of atrial fibrillation experienced the highest risk of HF associat

174 issue provides a clinical overview of atrial fibrillation, focusing on diagnosis, treatment, and prac

175 to October 2013 with newly diagnosed atrial fibrillation formed the study cohort (65 734 [44.8%] men

176 ith warfarin therapy in patients with atrial fibrillation from the perspective of the US health care

177 Radiofrequency catheter ablation for atrial fibrillation has become an important therapy for AF; how

178 ded warfarin dosing for patients with atrial fibrillation have demonstrated conflicting results.

179 tation had higher adjusted hazards of atrial fibrillation (hazard ratio [HR], 3.12; 95% confidence in

180 of CAD were linked to development of atrial fibrillation, heart failure, and death.

181 Early diagnosis of atrial fibrillation, ideally before the first complication occu

182 ug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recruited from 21 sites

183 idence, risk factors, and outcomes of atrial fibrillation in a cohort of critically ill patients with

184 enetic loci have been associated with atrial fibrillation in European and Asian ancestry groups.

185 the development of conditions such as atrial fibrillation in humans.

186 The excess risk of atrial fibrillation in individuals with type 1 diabetes increas

187 h the general population, the risk of atrial fibrillation in men with type 1 diabetes was slightly ra

188 icular pacing (RVP) increases risk of atrial fibrillation in patients with implantable cardioverter-d

189 The risk of atrial fibrillation in people with type 1 diabetes increased wi

190 rence of ventricular tachycardia/ventricular fibrillation in such patients.

191 oci were specifically associated with atrial fibrillation in the Japanese population after comparing

192 estigate genetic loci associated with atrial fibrillation in the Japanese population, we performed a

193 Over a third of patients with atrial fibrillation in this large outpatient registry received

194 detection from 60% to 70% of time in atrial fibrillation in unipolar recordings and from 0% to 62% i

195 reafter to cardiac arrest due to ventricular fibrillation, including rhythms shockable by an automati

196 Atrial fibrillation increased with age to surpass IART as the m

197 Adults with atrial fibrillation initiating dabigatran or warfarin therapy b

198 Atrial fibrillation is also a common complication and is not we

199 Catheter ablation of atrial fibrillation is associated with a risk of cerebral embol

200 nd frequently unrecognized, new-onset atrial fibrillation is associated with poor hospital outcomes.

201 This fibrillation is critically dependent on properties of th

202 reatment options to all patients with atrial fibrillation is difficult, despite recent improvements i

203 ry artery disease, heart failure, and atrial fibrillation is discussed in detail.

204 lants among patients with nonvalvular atrial fibrillation is not known.

205 Atrial fibrillation is one of the major cardiovascular health p

206 Fibrillation is strongly ion-sensitive, underlining the

207 Atrial fibrillation is the most common cardiac arrhythmia and l

208 llation are made, and the arrhythmia (atrial fibrillation) is indicative diagnosed from health, by ch

209 c disease was defined as a history of atrial fibrillation, ischemic heart diseases, or congestive hea

210 tion (PeAF), long-standing persistent atrial fibrillation (LPeAF), or paroxysmal atrial fibrillation

211 rillation, rotors potentially explain atrial fibrillation maintenance, but their ablation remains con

212 Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; men, 55.8

213 Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized 1:1:1 to administr

214 r of ventricular tachycardias or ventricular fibrillation, negatively affects short- and long-term su

215 tory of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsV

216 antially outside the South, including atrial fibrillation (Northwest), aortic aneurysm (Midwest), and

217 d electrocardiogram without pacing or atrial fibrillation noted on their baseline Jackson Heart Study

218 Detection was set to ventricular fibrillation number of intervals to detect=24/32, VT num

219 (1.4%) in the PFO closure group, and atrial fibrillation occurred in 29 patients (6.6%) after PFO cl

220 ne 2013, a total of 1,087 episodes of atrial fibrillation occurred in 418 (23%) individuals.

221 One serious adverse event (transient atrial fibrillation) occurred in 205 subjects who underwent PFO

222 ide polymorphisms was associated with atrial fibrillation (odds ratio=0.89 per SD change; 95% confide

223 Fibrillation of CysC therefore likely initiates from the

224 A purple color is formed during the fibrillation of lysozyme, a well-studied protein lacking

225 The cross-alpha fibrillation of PSMalpha3 facilitated cytotoxicity, sugg

226 tedly emphasized as a risk factor for atrial fibrillation or flutter (AF).

227 bserved six cases of self-terminating atrial fibrillation or flutter and six cases of partial electri

228 360-day complications, and shocks for atrial fibrillation or supraventricular tachycardia.

229 IF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies h

230 inical trials, enrolled patients with atrial fibrillation or venous thromboembolism, compared a novel

231 diac defibrillator discharge for ventricular fibrillation or ventricular tachycardia >240 bpm) and 36

232 urvival than those in refractory ventricular fibrillation (p = 0.017).

233 l fibrillation (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial sites are important;

234 nticoagulants, more than one third of atrial fibrillation patients still remain untreated.

235 patients if sources drive persistent atrial fibrillation (PeAF), long-standing persistent atrial fib

236 trial fibrillation, thereby promoting atrial fibrillation persistence.

237 However, up to 40% of an atrial fibrillation population may be asymptomatic.

238 the number of known genetic loci for atrial fibrillation, provide insights into the molecular basis

239 for ARISTOTLE-eligible patients with atrial fibrillation provides clinical benefits at an incrementa

240 echanisms sustaining human persistent atrial fibrillation (PsAF) is poorly understood.

241 in patients with shock-resistant ventricular fibrillation /pulseless ventricular tachycardia.

242 term survival in shock-resistant ventricular fibrillation/pulseless ventricular tachycardia; however,

243 Robust evidence from patients with atrial fibrillation randomized to NOACs or warfarin demonstrate

244 s >/=18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or rec

245 presence of surfactant/LPS, accelerates the fibrillation rate of CsgA by circumventing the lag phase

246 a significantly higher prevalence of atrial fibrillation (rate ratio [RR], 1.62; 95% CI, 1.20-21.8),

247 presented reentrant activity just in atrial fibrillation recordings accounting for approximately 80%

248 to first ventricular tachycardia/ventricular fibrillation recurrence.

249 ference was observed in terms of free atrial fibrillation-recurrence rates: 79.4% in control versus 7

250 stry for Better Informed Treatment of Atrial Fibrillation) registry, a prospective, nationwide, outpa

251 nted for stroke prevention during non-atrial fibrillation-related cardiac surgery.

252 Once diagnosed, atrial fibrillation requires chronic, multidimensional manageme

253 e PR interval comprises modulators of atrial fibrillation risk and obesity.

254 In human long-standing persistent atrial fibrillation, rotors potentially explain atrial fibrilla

255 utations that cause a genetic form of atrial fibrillation, S140G and V141M, drastically slow IKs deac

256 evalence of asymptomatic, subclinical atrial fibrillation (SCAF) in patients with pacemakers and pati

257 rior stroke, diabetes, pacemaker use, atrial fibrillation, slow gait speed, and nonfemoral access wer

258 tion, new or worsening heart failure, atrial fibrillation, stroke, deep venous thrombosis, cardiovasc

259 ate-quality evidence that concomitant atrial fibrillation surgery approximately doubles the likelihoo

260 g cardiac surgery undergo concomitant atrial fibrillation surgery?

261 ntribute to a better understanding of atrial fibrillation susceptibility and pathogenesis.

262 and NEBL genes, which are relevant to atrial fibrillation susceptibility.

263 ersistent or long-standing persistent atrial fibrillation, the outcomes of initial ablative strategie

264 ed by ventricular tachycardia or ventricular fibrillation, the rate of 1-year survival was higher in

265 enhance the occurrence of EBW during atrial fibrillation, thereby promoting atrial fibrillation pers

266 ion with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48),

267 ensing RF Ablation Clinical Trial for Atrial Fibrillation [TRAC-AF]; NCT02821351).

268 A total of 1585 patients with atrial fibrillation undergoing PVI from the Swedish Catheter Ab

269 dian age, 63.5 years) with persistent atrial fibrillation underwent epicardial thoracoscopic radiofre

270 paroxysmal (n=345; 42%) or persistent atrial fibrillation underwent postprocedural esophageal endosco

271 We found atrial fibrillation using automated detection (>/= 90 s in 30 m

272 ted ventricular tachycardia (VT)/ventricular fibrillation (VF) and Brugada syndrome-related symptoms,

273 After defibrillation of initial ventricular fibrillation (VF), it is crucial to prevent refibrillati

274 rapy for ventricular tachycardia/ventricular fibrillation (VF).

275 rst event of ventricular tachycardia (VT) or fibrillation (VF).

276 refractory out-of-hospital (OH) ventricular fibrillation (VF)/ventricular tachycardia (VT) cardiac a

277 prediction of very late recurrence of atrial fibrillation (VLRAF) occuring >12 months after catheter

278 New-onset atrial fibrillation was associated with a longer stay (hazard r

279 ed by ventricular tachycardia or ventricular fibrillation was associated with higher rates of long-te

280 gression analyses, clinical new-onset atrial fibrillation was associated with increased hospital mort

281 The rate of atrial fibrillation was higher in the PFO closure group than in

282 New-onset atrial fibrillation was not associated with survival after hosp

283 h normoalbuminuria, no excess risk of atrial fibrillation was noted in men with type 1 diabetes who h

284 Most atrial fibrillation was paroxysmal; less than 2% of admissions

285 New-onset atrial fibrillation was subclinical or went undocumented in 626

286 Hospital for Long-Standing Persistent Atrial Fibrillation), we sought to assess, in patients with sym

287 for warfarin therapy in patients with atrial fibrillation, we performed a cost-effectiveness analysis

288 o further define the genetic basis of atrial fibrillation, we performed large-scale, trans-ancestry m

289 acteristics from 14 206 patients with atrial fibrillation were integrated into a validated warfarin c

290 eless ventricular tachycardia or ventricular fibrillation were stratified by prompt (</=2 minutes) ve

291 ry failure, and new-onset subclinical atrial fibrillation, which occurred in 8% of admissions, were a

292 included 140 patients with paroxysmal atrial fibrillation, which was refractory to antiarrhythmic dru

293 on: Should patients with preoperative atrial fibrillation who are undergoing cardiac surgery undergo

294 uding 91330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescription o

295 cohorts of patients with non-valvular atrial fibrillation with incident exposure to dabigatran, rivar

296 on recruiting high-risk patients with atrial fibrillation with more than 2 stroke risk factors, with

297 etermine the association of new-onset atrial fibrillation with outcomes, including ICU length of stay

298 probability of a first occurrence of atrial fibrillation within the following 24 hours, we performed

299 Atrial fibrillation would have gone undetected in most patients

300 the VT zone, and 6 of 10 in the ventricular fibrillation zone.